SynthesisNaunyn-Schmiedeberg's archives of pharmacology2026
Role of SGLT2 inhibitors in cancer therapy-related cardiac dysfunction (CTRCD) in adults: systematic review and meta-analysis: SGLT2 inhibitors and CTRCD.
Synthesis in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Empagliflozin Protects Against Doxorubicin Cardiotoxicity: Integrative Assessment of Cardiac Kinetics and Electrophysiology Using Machine Learning in a Rat Model.Medical sciences (Basel, Switzerland) · 2026Article
- Cardioprotective effects of dapagliflozin against doxorubicin-induced cardiotoxicity in breast cancer patients with type 2 diabetes: a prospective study.BMC cancer · 2026Observational
- Beyond Hyperglycemia: The Role of Sodium-Glucose Cotransporter 2 Inhibitors in Cancer Treatment-related Cardiac Dysfunction.US cardiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Our primary objective is to evaluate the role of SGLT2 inhibitors in the protection against cancer therapy-related cardiac dysfunction (CTRCD) in adults with both cancer and type 2 diabetes mellitus. This is a systematic review and meta-analysis. A comprehensive search was conducted in five databases for studies published up to January 5th, 2025, using a PECO strategy. Seven studies were identified for quantitative analysis and included in our meta-analysis. Primary studies evaluating the use of SGLT2 inhibitors for the protection against CTRCD were included, specifically those in which CTRCD developed after chemotherapy and without a prior history of heart failure as the primary outcome. In the meta-analysis of 10,460 patients who received SGLT2i versus 12,815 in the control group, we found that SGLT2i use was associated with a 48% reduction in the risk of developing CTRCD (RR 0.52; 95% CI: 0.30-0.90; I
Indexed as
Identifiers
40748473What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.